What's Going On With ABVC Biopharma Stock Friday?
Portfolio Pulse from Henry Khederian
ABVC Biopharma Inc's shares are trading higher by 7% following the company's announcement of a term sheet to license global rights for CNS drugs targeting MDD and ADHD to AiBtl BioPharma for a valuation of $667 million. The deal includes a 46 million-share stock allocation from AiBtl, milestone cash payments of $7 million, and royalties potentially reaching $200 million. AiBtl intends to go public on NASDAQ in 2024.
October 27, 2023 | 3:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
ABVC Biopharma's stock is trading higher following a licensing deal with AiBtl BioPharma. The deal's terms, including a significant stock allocation and potential royalties, are likely driving the stock's increase.
The licensing deal with AiBtl BioPharma is a significant development for ABVC Biopharma. The terms of the deal, including a large stock allocation and potential royalties, are likely seen as positive by investors, driving the stock's increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100